Markets open

Eli Lilly and Company

LLY · NYSE

Symbol: LLY
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: NYSE

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people.

Key Issues

Bullish view

Third-quarter volume rose 53% and revenue increased 39%, with strong demand for Mounjaro and Zepbound supporting growth.

Bearish view

Realized prices fell 15%, so rapid volume growth is not translating one-for-one into revenue and leaves monetization under pressure.

Analyst Consensus

See all

Buy

23 analysts

$1,407

Current

—

Low

$1,550

Average

—

High

Average target implies +10.18% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Analyst Consensus

Buy

23 analysts

$1,407

Current

—

Low

$1,550

Average

—

High

Average target implies +10.18% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Buy across 23 analysts, with a mean price target of $1,400; no consensus low or high is provided, so the target cluster and full spread cannot be established. Among the available figures, Freedom Broker analyst Ilya Zubkov raised his target to $1,600 and kept Buy, while MarketBeat reports an aggregate target of $1,320.25; these are not a comparable set of individual analyst targets. No dated analyst rating or target revisions for the past week are supplied, so the direction of weekly revisions is unclear. The substantive tension in the evidence is whether strong Mounjaro and Zepbound demand and raised sales guidance can outweigh lower realized prices and Lilly’s trimmed adjusted earnings outlook.